央视新闻客户端：我的入党申请书丨胡必杰医生的新起点
fudan.edu.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fudan.edu.cn Daily Mail and Mail on Sunday newspapers.
我的入党申请书丨胡必杰医生的新起点
sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.
10x Genomics (NASDAQ:TXG) all appear ready to take healthy slices of the newly bolstered market for COVID-19 diagnostics.
Image source: Getty Images
Illumina is no doubt
the blue-chip player in the world of genomic sequencing. Its technology was used at the Shanghai Public Health Center to sequence the first published COVID-19 genome before it was even known as SARS-CoV-2. The company s sequencing technology continues to be utilized worldwide to identify new COVID strains that could pose a future threat to public health.
As the world s leading gene-sequencing company during the pandemic, Illumina has been busy. In fact, in Q4, the company s market-leading sequencer, the NovaSeq, had its second-best sales quarter in its five years on the market. Though its full-year 2020 revenue fell 9%, the company s business accelerated in the second half, growing by 17% from the first half. Management expects that trend to continue: Illumina recently raised its 2021 guidance it s now expecti